NYSE · XBI
Financial Services · Asset Management
$153.77
Up+$4.48 (+3.00%)
Updated Oct 11, 2026, 1:00 PM
SID Score
5.2/10
Composite research score
Smart Money
53/100
Neutral
Price performance · XBI
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
XBI closed at $153.77 after 20 trading sessions, down 2.43% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $149.32 | $154.50 | $149.03 | $153.77 | 12.14M |
| Oct 8, 2026 | $149.00 | $149.69 | $146.01 | $149.29 | 12.92M |
| Oct 7, 2026 | $149.37 | $152.40 | $148.63 | $150.23 | 9.54M |
| Oct 6, 2026 | $156.87 | $157.47 | $149.68 | $150.90 | 17.22M |
| Oct 5, 2026 | $155.56 | $156.73 | $152.56 | $156.19 | 6.99M |
| Oct 2, 2026 | $156.41 | $156.74 | $153.575 | $154.43 | 8.75M |
| Oct 1, 2026 | $156.99 | $159.0762 | $154.46 | $154.51 | 11.57M |
| Sep 30, 2026 | $157.84 | $159.98 | $156.48 | $157.68 | 6.87M |
| Sep 29, 2026 | $156.135 | $157.82 | $154.515 | $156.81 | 8.39M |
| Sep 28, 2026 | $154.66 | $157.63 | $153.7404 | $156.61 | 7.14M |
| Sep 25, 2026 | $156.80 | $157.17 | $153.8522 | $155.03 | 8.24M |
| Sep 24, 2026 | $154.83 | $156.82 | $152.56 | $156.05 | 13.8M |
| Sep 23, 2026 | $161.94 | $162.68 | $154.44 | $155.20 | 13.33M |
| Sep 22, 2026 | $159.11 | $162.48 | $158.42 | $161.87 | 7.64M |
| Sep 21, 2026 | $158.49 | $159.57 | $156.58 | $158.23 | 7.85M |
| Sep 18, 2026 | $158.21 | $159.19 | $155.89 | $156.72 | 9.88M |
| Sep 17, 2026 | $157.31 | $160.33 | $156.94 | $158.25 | 10.02M |
| Sep 16, 2026 | $154.37 | $156.04 | $152.50 | $154.18 | 8.85M |
| Sep 15, 2026 | $157.08 | $157.53 | $152.63 | $154.03 | 11.3M |
| Sep 14, 2026 | $156.86 | $158.965 | $156.20 | $157.60 | 6.18M |
The latest Smart Investors Daily articles mentioning XBI.
Company
Market Activity
Research & News
XBI research
Company profile and research snapshot.
In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI").
Consensus and target data currently published for this company.
No generated briefing is available yet.
Yahoo · Oct 4, 2026
XPH delivered 19% higher returns over five years despite half the volatility. XBI's 165 holdings offer broader exposure but with a 53% maximum drawdown.
Yahoo · Oct 2, 2026
Gilead shares are up 35% since Barron’s highlighted them, but our catalysts have yet to fully play out.
Yahoo · Sep 30, 2026
A 100% tariff on imported drugs just expanded to cover every drugmaker in the country, yet the biotech market's most closely watched fund treated it like a non-event. The reason says everything about who actually pays.
Yahoo · Sep 29, 2026
Smart Beta ETF report for XBI
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning XBI.
